The Potential Rise in the Price of G1 Therapeutics Inc. (GTHX) following insiders activity

EURN Stock
EURN Stock

G1 Therapeutics Inc.’s recently made public that its Director Velleca Mark A. unloaded Company’s shares for reported $0.18 million on Oct 18. In the deal valued at $11.70 per share,15,000 shares were sold. As a result of this transaction, Velleca Mark A. now holds 116,000 shares worth roughly $ 0.97 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Then, Velleca Mark A. sold 20,000 shares, generating $270,044 in total proceeds. Upon selling the shares at $13.50, the Director now owns 116,000 shares.

Before that, Malik Rajesh sold 18,000 shares. G1 Therapeutics Inc. shares valued at $282,746 were divested by the Chief Medical Officer at a price of $15.71 per share. As a result of the transaction, Malik Rajesh now holds 73,207 shares, worth roughly $0.61 million.

JP Morgan downgraded its G1 Therapeutics Inc. [GTHX] rating to an Underweight from a a Neutral in a research note published on Friday, November 04, 2021; the price target was decreased to $19 from $20. PT values the company’s stock at a premium of 56.21 to its Friday closing price. JP Morgan also remained covering GTHX and has decreased its forecast on September 30, 2021 with a “Neutral” recommendation from previously “an Overweight” rating. Raymond James revised its rating on November 17, 2020. It rated GTHX as “an Outperform” which previously was an “a Strong buy”.

Price Performance Review of GTHX

On Friday, G1 Therapeutics Inc. [NASDAQ:GTHX] saw its stock jump 4.92% to $8.32. On the same session, the stock had its day’s lowest price of $7.91, but rose to a high of $8.39. Over the last five days, the stock has lost -24.43%. G1 Therapeutics Inc. shares have fallen nearly -18.51% since the year began. Nevertheless, the stocks have fallen -48.55% over the past one year. While a 52-week high of $17.49 was reached on 09/14/22, a 52-week low of $3.84 was recorded on 06/16/22. SMA at 50 days reached $12.69, while 200 days put it at $9.07. A total of 0.88 million shares were traded, compared to the trading of 4.57 million shares in the previous session.

Levels Of Support And Resistance For GTHX Stock

The 24-hour chart illustrates a support level at 8.02, which if violated will result in even more drops to 7.73. On the upside, there is a resistance level at 8.50. A further resistance level may holdings at 8.69. The Relative Strength Index (RSI) on the 14-day chart is 29.01, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.17, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 85.31%. Stochastics %K at 10.62% indicates the stock is a buying.

How much short interest is there in G1 Therapeutics Inc.?

A steep rise in short interest was recorded in G1 Therapeutics Inc. stocks on Jul 14, 2022, dropping by -2.98 million shares to a total of 4.77 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 7.75 million shares. There was a decline of -62.47%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 12.57% of the overall stock float, the days-to-cover ratio (short ratio) fell to 3.26.

G1 Therapeutics Inc. [GTHX] – Who Are The Largest Shareholders?

In filings from Fisher Asset Management LLC, it is revealed that the company now owns 2,308,555 shares, or roughly 5.40% of the outstanding GTHX shares. In other words, the investor’s shares have fallen by -2,583 from its previous 13-F filing of 2311138.0. Over the last quarter, The Vanguard Group, Inc. sold -242,172 shares of G1 Therapeutics Inc., while BlackRock Fund Advisors sold -1,691,875 shares. At present, CHI Advisors LLC is holding 767,235 shares valued at $9.58 million. Millennium Management LLC owned 728,120 shares of the company at the time of its most recent 13F filing, worth $9.09 million.

The most recent change occurred on June 26, 2020 when ROTH Capital began covering the stock and recommended ‘”a Buy”‘ rating along with a $55 price target.


Please enter your comment!
Please enter your name here